American Association of Individual Investors3d
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Up 31.29%
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 31.29%, which has investors questioning if this is right time to sell.
Medical Xpress on MSN9d
Can a heart failure drug effectively treat a lethal form of ovarian cancer? Scientists hope the answer is 'yes'
Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...
Unlocking new insights into hereditary ovarian cancer risk
Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most prevalent and deadliest forms of ovarian cancer. Their work is published in ...
casereports.bmj10d
Non-bacterial thrombotic endocarditis in a patient with high-grade serous ovarian carcinoma: diagnostic challenges and management insights
A biopsy of the pelvic mass and analysis of ascitic fluid was consistent with high-grade serous carcinoma of tubo-ovarian origin. Following discussion at the gynaecology multidisciplinary team meeting ...
Equities Analysts Offer Predictions for ZNTL Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...
Hosted on MSN23d
Adding HIPEC Boosts Survival in Recurrent Ovarian Cancer
"When treating patients with late first relapse of serous or high-grade endometrioid ovarian ... of secondary cytoreductive surgery for ovarian carcinoma. As the landscape of ovarian cancer ...
Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals
Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.